J.P. Morgan Launches New Life Sciences Private Capital Team Targeting Investments in Innovative Healthcare Companies

Industry luminaries to act as Strategic Advisors to support new team

08-Nov-2022 - USA

J.P. Morgan Asset Management announced the launch of a new Life Sciences private equity team, Life Sciences Private Capital. The new team will invest in both early and growth stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology.

Computer-generated image

Symbolic image

The new team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a growth equity and private credit investment platform. The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, climate technology and life sciences sectors.

J.P. Morgan Asset Management has hired industry expert Dr. Stephen Squinto as Chief Investment Officer and Managing Partner of Life Sciences Private Capital. Dr. Squinto joins from OrbiMed Advisors and brings more than 30 years of experience in the biotechnology company building and investing space, having co-founded and built numerous biotechnology companies including Alexion Pharmaceuticals and acting as a key scientific founder of Regeneron Pharmaceuticals. 

Joining Dr. Squinto as Co-Managing Partners of the investment strategy are Dr. Gaurav Gupta and Ms. Anya Schiess. Dr. Gupta founded life science investment firm Ascendant BioCapital and was previously involved in private equity investments at OrbiMed Advisors. Ms. Schiess has over 25 years of experience in healthcare investing and most recently was Co-Founder and General Partner of Healthy Ventures. Full biographies are included below.

"Our new Life Sciences Private Capital team combines some of the industry's most revered biotech investors, operators and founders with J.P. Morgan's extensive healthcare ecosystem to capture compelling investment opportunities in the biotech sector, which is on the cusp of a golden age of therapeutic innovation," said Brian Carlin, Chief Executive Officer, J.P. Morgan Private Capital. "Through Steve, Gaurav and Anya's deep company-building experience, the team will bring a unique ability to partner with portfolio companies and add significant operational value beyond financial investment."

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.